NicoxSA announced that its Board of Directors appointed Andreas Segerros as Chief Executive Officer of Nicox S. A on May 13th, 2022, effective from June 1st, 2022, following the Board's decision to end the mandate of Michele Garufi, who has been Chairman, Chief Executive Officer and Co-Founder of the Company since its creation in 1996. Michele Garufi will remain as Board member of Nicox SA. Andreas Segerros has spent most of his career in global pharma, with executive positions (R&D, Marketing and Business Development) in the U.S., Europe and Japan, at Pharmacia, Pharmacia & Upjohn and Ferring, with the focus on specialty Pharma, ophthalmology in particular.

As Global Head of Ophthalmology at Pharmacia, Andreas launched XALATAN® (latanoprost), making it the industry's first billion-dollar ophthalmic drug. His venture capital experience comes from being Partner at the Scandinavian group Sunstone Capital, and also co-founded Eir Ventures. Andreas has made numerous investments in successful companies in Europe and the U.S.